SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

16 May 2026 Evaluate
The revenue for the March 2026 quarter is pegged at Rs. 12615.92 millions, about 22.44% up against Rs. 10303.53 millions recorded during the year-ago period.The company has announced a 44.98% increase in its profits to Rs . 4204.51  millions for the  quarter ended March 2026 compared to Rs. 2899.99 millions in the corresponding quarter in the previous year.Operating profit for the quarter ended March 2026 rose to 6140.74 millions as compared to 4378.41 millions of corresponding quarter ended March 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 12615.92 10303.53 22.44 45520.92 41161.49 10.59 45520.92 41161.49 10.59
Other Income 1063.57 437.18 143.28 3038.97 2150.75 41.30 3038.97 2150.75 41.30
PBIDT 6140.74 4378.41 40.25 19669.73 16576.93 18.66 19669.73 16576.93 18.66
Interest 61.65 34.46 78.90 180.73 228.37 -20.86 180.73 228.37 -20.86
PBDT 6079.09 4343.95 39.94 19245.54 16348.56 17.72 19245.54 16348.56 17.72
Depreciation 431.10 430.72 0.09 1762.43 1692.71 4.12 1762.43 1692.71 4.12
PBT 5647.99 3913.23 44.33 17483.11 14655.85 19.29 17483.11 14655.85 19.29
TAX 1443.48 1013.24 42.46 4487.60 3758.32 19.40 4487.60 3758.32 19.40
Deferred Tax 11.34 22.52 -49.64 -38.29 91.24 -141.97 -38.29 91.24 -141.97
PAT 4204.51 2899.99 44.98 12995.51 10897.53 19.25 12995.51 10897.53 19.25
Equity 164.76 164.76 0.00 164.76 164.76 0.00 164.76 164.76 0.00
PBIDTM(%) 48.67 42.49 14.54 43.21 40.27 7.29 43.21 40.27 7.29

Gland Pharma Share Price

2220.90 -11.05 (-0.50%)
04-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.35
Dr. Reddys Lab 1267.05
Cipla 1397.75
Zydus Lifesciences 1085.45
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×